Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03046524
Other study ID # PA15-0808
Secondary ID
Status Completed
Phase N/A
First received February 2, 2017
Last updated February 6, 2018
Start date October 6, 2015
Est. completion date October 16, 2017

Study information

Verified date February 2018
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Objectives:

1. Identify the clinical characteristics of parathyroid (PTH) cancer and PTH atypical neoplasms

2. Investigate if PTH carcinoma and atypical neoplasm present a biological behaviour and have a different impact on the health of the patients


Description:

Data between the years of 1/1/2002 and 12/31/2013 will be analyzed. The medical records of all adult patients that had a parathyroidectomy for primary PHPT in MD Anderson Cancer Center will be screened in order to identify patients that had a histopathological diagnosis of parathyroid carcinoma or atypical parathyroid neoplasm.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date October 16, 2017
Est. primary completion date October 16, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- All patients from MDACC diagnosed with PHPT that have a histopathological diagnosis of PTH carcinoma or atypical parathyroid neoplasm between the years 1/1/2002 and 12/31/2013

Exclusion Criteria:

- Pediatric patients

- Cases with incomplete records

- Patients where the follow-up will be less than six months

Study Design


Intervention

Other:
Chart Review
Data between the years of 1/1/2002 and 12/31/2013 analyzed.

Locations

Country Name City State
United States University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Information Collected on Clinical Characteristics of Parathyroid (PTH) Cancer and PTH Atypical Neoplasms by Conducting a Retrospective Chart Review 5 years
Primary Information Collected on PTH Carcinoma's Biological Behaviour and Impact on the Health of the Patients by Conducting a Retrospective Chart Review 5 years
Primary Information Collected on Atypical Neoplasm's Biological Behaviour and Impact on the Health of the Patients \by Conducting a Retrospective Chart Review 5 years
See also
  Status Clinical Trial Phase
Completed NCT00580320 - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Phase 1
Completed NCT01460030 - An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism Phase 3
Recruiting NCT05789680 - European Multicentric Study on Parathyroid Carcinoma
Completed NCT03280264 - Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Phase 3